Pfizer/GSK HIV Spin-Off ViiV Healthcare Debuts With Personalized Drugs in Portfolio

According to ViiV CEO Dominique Limet, the new company’s unique structure has the potential to “re-energize” the pharmaceutical industry’s involvement in driving HIV treatment innovation and improving access.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.